Bristol Myers Squibb reports positive Phase 3 results for Camzyos in adolescents with oHCM
The study showed a statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 compared with placebo
The study showed a statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 compared with placebo
Sabitha highlighted the growing relevance of minimally invasive therapies in modern medicine
The company is rolling out ARTEMIS, a next-generation AI platform for capsid design
The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 10, 2026
Projects selected for advancement will move forward through the Harvard Office of Technology Development’s processes for sponsored research agreements
Backed by two CAP - accredited genomics labs in Delhi NCR and Mumbai, supporting oncology, reproductive health, neurology, transplant immunology, and rare diseases
The acquisition combines Firstsource’s market-leading AI and automation capabilities with TeleMedik’s operational footprint in Puerto Rico
Preclinical studies show that 4P004 modulates multiple biological markers across the joint, potentially slowing structural damage while improving function
MH002, a rationally designed live microbial consortium, combines six well-characterized commensal strains to target disease-specific mechanisms
Subscribe To Our Newsletter & Stay Updated